The search of lncRNA biomarkers in PCa is exemplified by PCA3, a well characterized lncRNA that has been approved by the FDA for clinical decisions about repeat biopsy of prostate cancer [35]. This evidence concerns the gene PCA3 and prostate carcinoma.